Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning and Dissemination Grant - Institute Community Support

Université de Sherbrooke

$10,000.00

Preclinical multilaboratory studies for cancer immunotherapy

EF 2023-24

Résumé
Successfully translating novel cancer therapies from the lab to patients is a slow and difficult process. Contributing difficulties include poor experimental design and a lack of reproducibility. Moreover, another challenge has been collaboration between labs, including methods and data sharing. One approach to directly address these issues is the multilab preclinical study, where several labs conduct the same experiments using a common protocol. Akin to typical multicenter clinical trials (i.e., a gold standard approach in clinical research), multilab studies assess generalizability between labs, help complete adequately powered studies more efficiently, and promote knowledge exchange between research groups. To date, no multilab studies have been conducted to test cancer therapies. Here we propose a pan-Canadian meeting to convene key investigators, trainees, and highly-qualified personnel who are studying promising cancer immunotherapies. Through a day long meeting, along with pre and post meeting activities, we will determine key elements that should be considered for the world's first multilab studies of cancer therapies. In particular, chimeric antigen receptor T-cells, tumour infiltrating lymphocytes, oncolytic viruses, and natural killer cells will be considered, as well as best models and approaches to adopt. Our meeting will also seek input from veterinarians, scientists that study optimization of team collaborations, and researchers with expertise in multicenter study data management. We have engaged a wide group of knowledge users who will help shape meeting outputs. In order to maximize reach of our meeting, we have secured matching funds from BioCanRx, Canada's major funder of academic immune oncology research. This meeting will set the stage for the first Canadian preclinical multicenter study in cancer immunotherapy, with the aim of improving successful translation of these interventions.
Programme
Planning and Dissemination Grant - Institute Community Support
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
487925
Name
Tai Lee-Hwa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Planning and Dissemination Grants
Projecttitle
Preclinical multilaboratory studies for cancer immunotherapy
Programtype2
Miscellaneous Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Cancer Immunotherapy; Chimeric Antigen Receptor T Cell Therapy; Experimental Rigour; Multilaboratory Study; Natural Killer Cell Therapy; Oncolytic Virus Therapy; Translation; Tumour Infiltrating Lymphocyte Therapy
Abstract
Successfully translating novel cancer therapies from the lab to patients is a slow and difficult process. Contributing difficulties include poor experimental design and a lack of reproducibility. Moreover, another challenge has been collaboration between labs, including methods and data sharing. One approach to directly address these issues is the multilab preclinical study, where several labs conduct the same experiments using a common protocol. Akin to typical multicenter clinical trials (i.e., a gold standard approach in clinical research), multilab studies assess generalizability between labs, help complete adequately powered studies more efficiently, and promote knowledge exchange between research groups. To date, no multilab studies have been conducted to test cancer therapies. Here we propose a pan-Canadian meeting to convene key investigators, trainees, and highly-qualified personnel who are studying promising cancer immunotherapies. Through a day long meeting, along with pre and post meeting activities, we will determine key elements that should be considered for the world's first multilab studies of cancer therapies. In particular, chimeric antigen receptor T-cells, tumour infiltrating lymphocytes, oncolytic viruses, and natural killer cells will be considered, as well as best models and approaches to adopt. Our meeting will also seek input from veterinarians, scientists that study optimization of team collaborations, and researchers with expertise in multicenter study data management. We have engaged a wide group of knowledge users who will help shape meeting outputs. In order to maximize reach of our meeting, we have secured matching funds from BioCanRx, Canada's major funder of academic immune oncology research. This meeting will set the stage for the first Canadian preclinical multicenter study in cancer immunotherapy, with the aim of improving successful translation of these interventions.
Competitiondate
202307
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tai, Lee-Hwa; Bell, John C; Lalu, Manoj M
Approvedterm
1 an 0 mois
Cihrcontribution2
ICR~ $10,000~ $0~